Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibrinogen single-component sealant - PPL Therapeutics

Next Previous
X
Search
Drug Profile

Fibrinogen single-component sealant - PPL Therapeutics

Alternative Names: Fibrin 1 sealant - PPL Therapeutics; Fibrin I; Fibrinogen - PPL Therapeutics; Single-component fibrin sealant - PPL Therapeutics

Latest Information Update: 10 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Blood coagulation disorders; Wounds

Most Recent Events

  • 14 May 2003 PPL Therapeutics will now seek approval for fibrin I as a device
  • 19 Feb 2001 This product is available for licensing in USA, Europe and Japan (http://www.ppl-therapeutics.com)
  • 19 Feb 2001 Preclinical development for Coagulation disorders in USA (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top